Answering Your Frequently Asked Questions
Prepare for the Novel CNS Biomarkers Summit Europe with this comprehensive FAQ guide covering registration, agenda themes, networking opportunities, partnership options and more. This resource is designed to help you navigate the only European meeting dedicated exclusively to advancing fluid, imaging and digital biomarkers for CNS drug development.
Can't find what you're looking for? Get in touch at info@hansonwade.com for more information.
General
The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging and digital biomarkers for CNS drug development. The event brings together biomarker, translational medicine, neuroscience, precision medicine, bioanalytical and clinical development leaders to accelerate the discovery, validation and implementation of next-generation CNS biomarkers.
Through expert-led presentations, workshops and networking sessions, the summit explores:
- Blood-based biomarkers for neurodegenerative diseases
- Imaging biomarkers and multimodal approaches
- Digital cognitive, EEG and wearable-based endpoints
- Biomarker assay validation and standardisation
- Regulatory strategies and biomarker qualification
- Patient stratification, target engagement and clinical trial optimisation
The Novel CNS Biomarkers Summit Europe will take place 30th November - 2nd December 2026 at the Hilton London Olympia, London, UK.
Visit the Venue Page for full location and accommodation details.
Event Content
Yes. Unlike broader neuroscience, neurology or drug development meetings, the Novel CNS Biomarkers Europe Summit is focused exclusively on biomarker innovation and implementation across CNS drug development.
This meeting is:
- Biomarker-focused: Dedicated entirely to CNS biomarker development
- Translation-driven: Exploring how biomarkers can improve clinical decision-making
- Technology-led: Covering fluid, imaging and digital biomarker modalities
- Industry-focused: Bringing together biopharma leaders actively advancing CNS pipelines
Sessions are designed to address the practical challenges of biomarker discovery, validation, assay harmonisation and clinical implementation.
Yes. The Novel CNS Biomarkers Summit Europe provides comprehensive coverage of the most important biomarker approaches currently shaping CNS drug development, including:
- Blood-based biomarkers
- CSF and fluid biomarker assays
- Imaging biomarkers
- Digital cognitive biomarkers
- EEG and wearable-generated data
- Multi-omics and multimodal biomarker strategies
- Biomarker validation and qualification
Attendees will gain practical insights into how these technologies are being used to strengthen patient selection, demonstrate target engagement and generate earlier signals of efficacy.
Yes. The Novel CNS Biomarkers Summit Europe programme features case studies and biomarker strategies across 6+ CNS indications, helping attendees understand both disease-specific and cross-indication approaches.
Key disease areas include:
- Alzheimer's disease
- Parkinson's disease
- ALS
- Epilepsy
- Schizophrenia
- Multiple System Atrophy (MSA)
- Additional neurodegenerative and neurological disorders
Yes. The Novel CNS Biomarkers Summit Europe features a dedicated Pre-Conference Workshop Day designed to provide a deeper, more practical exploration of the technologies and strategies shaping the future of CNS biomarker development. Attendees can participate in two interactive workshops focused on the discovery, validation and implementation of next-generation biomarkers for neurological diseases.
The workshop programme includes:
Workshop A: Mastering α-Synuclein Biomarkers Across Fluid & Imaging Modalities to Accelerate Parkinson’s Disease Drug Development
Nuno Pires, Senior Manager Rare Diseases & Modalities In Vivo Pharmacology and Translation, Bial
Discussion Points:
- Explore emerging blood-based and fluid biomarker technologies
- Understand approaches to biomarker discovery and validation
- Discuss assay development, sensitivity and reproducibility challenges
- Learn how fluid biomarkers are being applied across CNS drug development programmes
- Gain practical insights into generating robust and clinically meaningful biomarker data
Workshop B: Overcoming Assay Harmonisation & Validation Challenges to Ensure Cross-Trial Comparability & Regulatory Acceptance
Nanh Nguyen, Translational Medicine Biomarker Lead, UCB
Discussion Points:
- Examine the latest innovations in imaging biomarkers
- Understand how imaging approaches can support patient stratification and target engagement
- Explore strategies for integrating imaging biomarkers into clinical development programmes
- Discuss opportunities and challenges associated with biomarker validation and implementation
- Learn from experts driving biomarker adoption across CNS indications
These workshops are designed to go beyond traditional conference presentations, giving attendees the opportunity to engage directly with subject matter experts, discuss real-world challenges and gain practical insights they can apply within their own biomarker programmes. The sessions are specifically intended to help accelerate CNS biomarker discovery and validation through focused discussion and collaborative learning.
Yes. The summit is designed to maximise meaningful networking opportunities between biomarker leaders, translational scientists, neuroscientists and clinical development professionals.
Attendees can connect with:
- Biomarker and translational medicine leaders
- Neuroscience and clinical development experts
- Bioanalytical and precision medicine specialists
- Senior decision-makers from leading biopharma organisations
Networking opportunities include:
- Dedicated networking breaks
- Interactive discussion sessions
- Workshop-based collaboration
- Speaker networking opportunities
- Informal meetings throughout the event
With over 8 hours of in-person networking, attendees can build valuable partnerships and exchange practical insights.
Yes. The Novel CNS Biomarkers Summit Europe brings together a senior faculty of biomarker, translational medicine, neuroscience and clinical development leaders who are at the forefront of advancing fluid, imaging and digital biomarkers for CNS drug development.
Attendees will hear directly from experts including:
- Nanh Nguyen, Translational Medicine Biomarker Lead, UCB
- Joseph Sutton, Biomarker Studies Asset Manager, Roche
- Elia Hall, Senior Scientist, Biosample Project Leader, Roche
- Jessica Nakhle, Director & Head of Clinical Biomarkers Neuroscience & Immuno-Inflammation, Translational Medicine, Servier
- Jordi Clarimon, Neurological Disorders & Biofluid Specialist, Lundbeck
- Isabella Premoli, Director, Translational Medicine, Saniona
- Sarah Almond, Vice President, Translational Biology, NRG Therapeutics
- Amelie Schreieck, Senior Manager, Biomarker Development, Immunic Therapeutics
- Nuno Pires, Senior Manager Rare Diseases & Modalities In Vivo Pharmacology and Translation, Bial
- Valerie Daggett, Founder & Chief Executive Officer, AltPep
- Kiri Granger, Co-Founder & Chief Scientific Officer, Monument Therapeutics
- Tauseef Butt, President & Chief Executive Officer, Progenra
- Aleksandra Zemla, Clinical Biomarkers Consultant, Dompé
Across the three-day programme, attendees will hear directly from the experts developing and implementing biomarker strategies to improve patient stratification, demonstrate target engagement, generate regulatory-ready data and accelerate therapeutic development across Alzheimer's disease, Parkinson's disease, ALS, schizophrenia, epilepsy, MSA and other CNS indications.
With representation spanning global pharma, biotech, translational medicine teams and emerging CNS innovators, the summit provides a unique opportunity to learn from and network with the leaders shaping the future of CNS biomarker development.
Yes. The Novel CNS Biomarkers Summit Europe features a dedicated Scientific Poster Session, providing attendees with the opportunity to showcase their latest research, gain valuable feedback from industry experts and connect with leaders driving innovation in CNS biomarker development.
The poster session is designed to create a relaxed and collaborative environment where researchers, biomarker experts and translational medicine leaders can exchange ideas and discuss emerging science.
Presenting a poster offers the opportunity to:
- Demonstrate thought leadership within the CNS biomarker field
- Gain visibility for your research and biomarker innovations
- Engage in meaningful discussions with fellow scientists and industry peers
- Receive direct feedback on your work from biomarker and neuroscience experts
- Raise your profile among potential collaborators, partners and industry stakeholders
To submit a poster, you must first register for the summit and submit an abstract for review. Accepted presenters will receive further guidance on poster requirements and submission deadlines.
Whether you are developing novel fluid biomarkers, advancing imaging technologies, exploring digital measures or validating translational biomarker strategies, the poster session is an excellent opportunity to showcase your work and contribute to the future of precision CNS drug development.
More details about the poster session can be found here.
Attendance
Yes. CNS biomarker development is entering a pivotal period driven by major scientific and commercial momentum. Recent advances in blood-based biomarkers, digital measures and ultrasensitive analytical technologies are transforming how neurological diseases are diagnosed and studied. At the same time, high CNS clinical trial failure rates continue to create demand for better biomarkers that can improve patient selection and demonstrate treatment effect earlier.
The Novel CNS Biomarkers Summit Europe is specifically designed to address these challenges by bringing together the experts developing the next generation of CNS biomarkers.
The Novel CNS Biomarkers Summit Europe attracts a highly focused audience of professionals responsible for advancing biomarker-driven CNS drug development.
This event is designed for leaders working across:
- Biomarker Development
- Translational Medicine
- Neuroscience
- Clinical Development
- Precision Medicine
- Bioanalytics
- Multi-Omics
- Drug Discovery
- Medical Affairs
- Regulatory Science
Attendees represent biotech, pharmaceutical and technology organisations actively developing therapies for neurodegenerative and neurological disorders.
Attendees can expect to:
- Learn from 16+ expert speakers
- Explore biomarker strategies across 6+ CNS indications
- Discover emerging fluid, imaging and digital biomarker technologies
- Gain practical insights into assay validation and implementation
- Network with 60+ biomarker and translational leaders
- Identify opportunities to improve CNS clinical trial success rates
The Novel CNS Biomarkers Summit Europe delivers actionable insights that can be applied from early discovery through late-stage clinical development.
Attending Organisations Include
Partnership Opportunities
Partnering with the Novel CNS Biomarkers Summit Europe provides direct access to an audience of biomarker, translational medicine and neuroscience leaders actively seeking technologies, services and strategic partnerships to advance CNS drug development.
As a partner, you can:
- Position your brand alongside leading CNS innovators
- Demonstrate thought leadership
- Showcase technologies and solutions
- Generate qualified commercial opportunities
- Build relationships with senior decision-makers
- Increase visibility among key stakeholders across biotech and pharma
Yes. A range of tailored partnership packages are available for organisations supporting CNS biomarker development and neurological drug development programs.
Available opportunities may include:
- Speaking presentations
- Panel participation
- Hosted roundtables
- Exhibition booths
- Branding opportunities
- Networking sponsorships
- Additional delegate passes
- Lead generation opportunities
Partnership packages can be customised to align with your commercial objectives and target audience.
Yes. Partnering with the Novel CNS Biomarkers Summit Europe provides direct access to a highly targeted audience of biomarker, translational medicine, neuroscience, clinical development and precision medicine leaders actively advancing CNS therapeutic programmes.
Unlike broader neurology or drug development events, this summit brings together a focused community dedicated specifically to the discovery, validation and implementation of fluid, imaging and digital biomarkers across CNS indications.
As a partner, you can:
- Connect directly with biomarker and translational medicine decision-makers
- Showcase technologies and solutions to organisations actively investing in CNS biomarker strategies
- Build relationships with leaders from biotech, pharma and diagnostic companies
- Position your brand as a key contributor to the future of precision neuroscience
- Generate high-quality commercial opportunities through targeted networking and thought leadership activities
- Increase visibility among attendees seeking partners to support biomarker discovery, validation and clinical implementation efforts
With attendees representing organisations across Alzheimer's disease, Parkinson's disease, ALS, epilepsy, schizophrenia, MSA and other CNS indications, partners can engage with prospective customers and collaborators all in one place.
You can contact us at sponsor@hansonwade.com and a member of the team will get back to you shortly.
Gain Approval
The Novel CNS Biomarkers Summit Europe offers a unique opportunity to gain practical insights, benchmark your biomarker strategy against industry leaders and bring back actionable learnings that can directly support your organisation's CNS drug development goals.
By attending, you will be able to:
- Learn from 60+ biomarker and translational medicine leaders
- Explore the latest advances in fluid, imaging and digital biomarkers
- Gain practical strategies to improve patient stratification, target engagement and efficacy assessment
- Benchmark your approach against leading organisations including Roche, Lundbeck, UCB and others
- Identify new technologies, partners and solutions that could accelerate internal programmes
- Return with actionable insights that can be shared across your wider team
Europe is becoming a major hub for CNS biomarker innovation, driven by advances in blood-based biomarkers, digital measures and ultrasensitive analytical technologies. At the same time, many late-stage CNS clinical trials continue to face significant challenges, placing increased importance on reliable biomarkers that can improve decision-making throughout development.
Attending this summit will help you stay ahead of emerging trends, understand evolving best practices and evaluate the biomarker strategies that are shaping the future of CNS drug development.
Yes. The Novel CNS Biomarkers Summit Europe provides a dedicated environment to expand your technical knowledge, stay current with emerging biomarker innovations and strengthen your professional network within the CNS community.
Attendees will:
- Gain exposure to cutting-edge biomarker science and technologies
- Learn directly from industry experts and experienced practitioners
- Participate in interactive workshops and discussion sessions
- Develop new perspectives on translational and clinical development challenges
- Build relationships with peers facing similar scientific and operational challenges
Attendees can maximise the value of attendance by bringing back insights and recommendations that benefit their wider organisation.
Following the summit, you may be able to:
- Share key learnings through an internal presentation or debrief
- Identify new biomarker technologies and approaches for evaluation
- Recommend process improvements based on industry best practices
- Report on emerging trends impacting future development strategies
- Highlight competitive intelligence gathered from industry leaders and peers
Yes. Consider the following:
Subject: Approval Request to Attend the Novel CNS Biomarkers Summit Europe
Dear [Manager Name],
I am writing to request approval to attend the Novel CNS Biomarkers Summit Europe, taking place 30th November - 2nd December 2026 in London, UK. This meeting is the only European meeting dedicated exclusively to advancing fluid, imaging and digital biomarkers for CNS drug development, bringing together leaders across biomarker research, translational medicine, neuroscience, precision medicine and clinical development.
This year's agenda is closely aligned with our work in [insert area of responsibility], particularly our efforts related to [current project, therapeutic area or strategic priority].
Several sessions focus on topics directly relevant to our team's objectives, including biomarker validation, blood-based biomarkers, imaging technologies, digital endpoints, patient stratification, target engagement and regulatory-ready biomarker development. These discussions would provide valuable insight into emerging best practices and innovative approaches being adopted across the CNS biomarker landscape.
By attending, I would be able to:
- Gain insight into the latest advances in fluid, imaging and digital biomarkers for CNS drug development
- Learn from biomarker, translational medicine and neuroscience leaders from organisations including Roche, UCB, Lundbeck, Servier, AltPep, Bial, NRG Therapeutics and Saniona
- Benchmark our current biomarker strategy against peers tackling similar scientific and clinical development challenges
- Explore practical approaches to biomarker discovery, validation and implementation across multiple CNS indications
- Identify new technologies, solutions and potential collaborators relevant to our programmes
- Participate in dedicated workshops focused on accelerating CNS biomarker discovery and validation
Specifically, I believe the knowledge gained could support our work on [insert programme, initiative or business objective].
Following the conference, I will ensure the value of attendance is shared across the team by:
- Preparing a summary report of key takeaways
- Sharing relevant presentations, insights and industry updates
- Presenting recommendations applicable to our current research and development activities
- Highlighting emerging biomarker technologies and industry trends
- Identifying potential collaboration, partnership and vendor opportunities discussed during the event
The summit attracts a focused audience of biomarker, translational medicine and neuroscience leaders and features case studies spanning Alzheimer's disease, Parkinson's disease, ALS, epilepsy, schizophrenia, MSA and other CNS indications.
I am confident that the knowledge, connections and best practices gained from this event will support both my professional development and our team's objectives as we continue to advance [insert project or company goal].
Thank you for considering my request. I would be happy to discuss the event in more detail and explain how attendance could support our wider business goals.
Kind regards,
[Your Name]
[Job Title]
Yes. Visit our dedicated Gain Approval Page for more information on who you will meet and benefits of attending the conference.
Registration
Yes. You can register directly through the event website on our Registration Page.
Please ensure you review the pricing & registration details.
If you have any registration questions or would like information regarding group bookings, please contact the team at info@hansonwade.com.
Yes. Conference Days are FREE* for eligible biopharma. You can register your free pass on our Registration Page.
Please ensure you review the pricing & registration details.
If you have any registration questions, please contact the team at info@hansonwade.com.
Yes. Discounts ranging from 10% to 20% are available for teams registering two or more attendees from the same organisation.
Attending as a team can help organisations:
- Align on biomarker and translational medicine strategies
- Bring back a broader range of insights to the business
- Maximise networking opportunities with industry peers and potential partners
- Ensure key stakeholders gain value from the discussions covering fluid, imaging and digital biomarkers across 6+ CNS indications
Find out more about group discounts on our Registration Page, or contact us at info@hansonwade.com.
Please note, group discounts are only available to service and solution provider organisations.
Explore the Agenda
Discover the latest case studies and practical strategies shaping the future of CNS biomarker development from Lundbeck, Roche, UCB & more.
Partner With Us
Position your brand alongside Europe's leading biomarker innovators and connect with decision-makers actively seeking new technologies and partners.
Join Biopharma Experts
Exchange ideas with biomarker, translational medicine and clinical development leaders tackling the biggest challenges in neurodegenerative drug development.